GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (TSXV:ARCH) » Definitions » Cyclically Adjusted PB Ratio

Arch Biopartners (TSXV:ARCH) Cyclically Adjusted PB Ratio : (As of May. 01, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Arch Biopartners Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Arch Biopartners Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Arch Biopartners's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Biopartners Cyclically Adjusted PB Ratio Chart

Arch Biopartners Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Arch Biopartners Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Arch Biopartners's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Arch Biopartners's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arch Biopartners's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arch Biopartners's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Arch Biopartners's Cyclically Adjusted PB Ratio falls into.



Arch Biopartners Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Arch Biopartners's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Arch Biopartners's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.091/125.4675*125.4675
=-0.091

Current CPI (Dec. 2023) = 125.4675.

Arch Biopartners Quarterly Data

Book Value per Share CPI Adj_Book
201403 -0.003 98.604 -0.004
201406 -0.006 99.473 -0.008
201409 0.000 99.394 0.000
201412 -0.003 98.367 -0.004
201503 0.009 99.789 0.011
201506 0.006 100.500 0.007
201509 0.003 100.421 0.004
201512 0.000 99.947 0.000
201603 -0.004 101.054 -0.005
201606 -0.001 102.002 -0.001
201609 -0.005 101.765 -0.006
201612 -0.009 101.449 -0.011
201703 -0.005 102.634 -0.006
201706 -0.010 103.029 -0.012
201709 -0.010 103.345 -0.012
201712 -0.016 103.345 -0.019
201803 -0.004 105.004 -0.005
201806 -0.005 105.557 -0.006
201809 -0.015 105.636 -0.018
201812 -0.031 105.399 -0.037
201903 -0.039 106.979 -0.046
201906 -0.039 107.690 -0.045
201909 -0.045 107.611 -0.052
201912 -0.059 107.769 -0.069
202003 -0.057 107.927 -0.066
202006 -0.043 108.401 -0.050
202009 -0.064 108.164 -0.074
202012 -0.078 108.559 -0.090
202103 -0.093 110.298 -0.106
202106 0.000 111.720 0.000
202109 -0.063 112.905 -0.070
202112 -0.065 113.774 -0.072
202203 -0.063 117.646 -0.067
202206 -0.064 120.806 -0.066
202209 -0.072 120.648 -0.075
202212 -0.072 120.964 -0.075
202303 -0.087 122.702 -0.089
202306 -0.092 124.203 -0.093
202309 -0.088 125.230 -0.088
202312 -0.091 125.468 -0.091

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Arch Biopartners  (TSXV:ARCH) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Arch Biopartners Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Arch Biopartners's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Arch Biopartners (TSXV:ARCH) Business Description

Traded in Other Exchanges
N/A
Address
545 King Street West, Toronto, ON, CAN, M5V 1M1
Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. It's under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.